Keely Chevallier, MD
Otolaryngology · Reno, NVNPI 1780973354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 31.8% of the total. Reporting peaked in 2019 at $111 and has fallen 73.5% since, to $29 in 2025. That places this record below the midpoint for otolaryngology clinicians in NV, where the typical reported total is $1,885.
Across 12 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$83
- Regeneron Healthcare Solutions, Inc.$59
- Merck$29
- Amgen$26
- Bristol Myers Squibb$25
- Covidien LP$14
- plus $26 from 2 others
What the payments were for
- Food & beverage$24995%
- Education$135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 3 | $83 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Merck | 1 | $29 |
| Amgen | 2 | $26 |
| Bristol Myers Squibb | 1 | $25 |
| Covidien LP | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$262 in reported general payments places this provider in the 15th percentile of 41 otolaryngology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 29 | $1,122 |
| Ofloxacin | 42 | $1,109 |
| Omeprazole | 54 | $899 |
| Mupirocin | 79 | $660 |
| Azelastine Hcl | 22 | $344 |
| Levothyroxine Sodium | 16 | $149 |
| Ondansetron OdtOndansetron | 14 | $125 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $64 |
| Oxycodone Hcl | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Reno
- Jeremy LoughReno$4K
- Leah HauserReno$2K
- Courtney GarrettReno$1K
- Stacey HudsonReno$1K
- Anthony ZamboniReno$843
- David MathisReno$565
- Joshua MeierReno$121
- Robert ChaseReno$108
- Bud WestReno$61
- Martha Jenny van DuyneReno$46
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.